keyword
https://read.qxmd.com/read/38651409/efficient-expression-of-functionally-active-aflibercept-with-designed-n-glycans
#1
JOURNAL ARTICLE
Tahereh Keshvari, Stanislav Melnik, Lin Sun, Ali Niazi, Farzaneh Aram, Ali Moghadam, Benjamin Kogelmann, Gordana Wozniak-Knopp, Somanath Kallolimath, Amin Ramezani, Herta Steinkellner
Aflibercept is a therapeutic recombinant fusion protein comprising extracellular domains of human vascular endothelial growth factor receptors (VEGFRs) and IgG1-Fc. It is a highly glycosylated protein with five N-glycosylation sites that might impact it structurally and/or functionally. Aflibercept is produced in mammalian cells and exhibits large glycan heterogeneity, which hampers glycan-associated investigations. Here, we report the expression of aflibercept in a plant-based system with targeted N-glycosylation profiles...
April 7, 2024: Antibodies
https://read.qxmd.com/read/38650939/poly-i-c-elicits-broader-and-stronger-humoral-and-cellular-responses-to-a-plasmodium-vivax-circumsporozoite-protein-malaria-vaccine-than-alhydrogel-in-mice
#2
JOURNAL ARTICLE
Tiffany B L Costa-Gouvea, Katia S Françoso, Rodolfo F Marques, Alba Marina Gimenez, Ana C M Faria, Leonardo M Cariste, Mariana R Dominguez, José Ronnie C Vasconcelos, Helder I Nakaya, Eduardo L V Silveira, Irene S Soares
Malaria remains a global health challenge, necessitating the development of effective vaccines. The RTS,S vaccination prevents Plasmodium falciparum (Pf) malaria but is ineffective against Plasmodium vivax (Pv) disease. Herein, we evaluated the murine immunogenicity of a recombinant PvCSP incorporating prevalent polymorphisms, adjuvanted with Alhydrogel or Poly I:C. Both formulations induced prolonged IgG responses, with IgG1 dominance by the Alhydrogel group and high titers of all IgG isotypes by the Poly I:C counterpart...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650936/outer-membrane-vesicles-derived-from-bordetella-pertussis-are-potent-adjuvant-that-drive-th1-biased-response
#3
JOURNAL ARTICLE
Bernarda Pschunder, Lucia Locati, Oriana López, Pablo Martin Aispuro, Eugenia Zurita, Matthew Stuible, Yves Durocher, Daniela Hozbor
For several years, we have been committed to exploring the potential of Bordetella pertussis -derived outer membrane vesicles (OMV Bp ) as a promising third-generation vaccine against the reemerging pertussis disease. The results of our preclinical trials not only confirm its protective capacity against B. pertussis infection but also set the stage for forthcoming human clinical trials. This study delves into the examination of OMV Bp as an adjuvant. To accomplish this objective, we implemented a two-dose murine schedule to evaluate the specific immune response induced by formulations containing OMV Bp combined with 3 heterologous immunogens: Tetanus toxoid (T), Diphtheria toxoid (D), and the SARS-CoV-2 Spike protein (S)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650925/bi-isotype-immunoglobulins-enhance-antibody-mediated-neutrophil-activity-against-plasmodium-falciparum-parasites
#4
JOURNAL ARTICLE
Rodney Ogwang, Lewis Murugu, Irene N Nkumama, Lydia Nyamako, Oscar Kai, Kennedy Mwai, Linda Murungi, Richard Idro, Philip Bejon, James Tuju, Sam Muchina Kinyanjui, Faith H A Osier
BACKGROUND: Malaria remains a major global health priority, and monoclonal antibodies (mAbs) are emerging as potential new tools to support efforts to control the disease. Recent data suggest that Fc-dependent mechanisms of immunity are important mediators of protection against the blood stages of the infection, but few studies have investigated this in the context of mAbs. We aimed to isolate mAbs agnostic to cognate antigens that target whole merozoites and simultaneously induce potent neutrophil activity measured by the level of reactive oxygen species (ROS) production using an antibody-dependent respiratory burst (ADRB) assay...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38650583/the-cost-effectiveness-of-a-bimekizumab-versus-il-17a-inhibitors-treatment-pathway-in-patients-with-active-axial-spondyloarthritis-in-scotland
#5
JOURNAL ARTICLE
Michael F Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom
AIMS: To estimate the cost-effectiveness of a treatment-pathway initiated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, in patients with axial spondyloarthritis (axSpA) compared with IL-17A inhibitors, ixekizumab, and secukinumab, from the National Health Service (NHS) of Scotland perspective. METHODS: The axSpA treatment-pathway was modeled using a one-year decision tree followed by a lifetime Markov model...
April 23, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38647337/targeting-t-bet-expressing-b-cells-for-therapeutic-interventions-in-autoimmunity
#6
JOURNAL ARTICLE
Athanasios Sachinidis, Malamatenia Lamprinou, Theodoros Dimitroulas, Alexandros Garyfallos
Apart from serving as a Th1 lineage commitment regulator, transcription factor T-bet is also expressed in other immune cell types and thus orchestrates their functions. In case of B cells, more specifically, T-bet is responsible for their isotype switching to specific IgG sub-classes (IgG2a/c in mice and IgG1/3 in humans). In various autoimmune disorders, such as systemic lupus erythematosus and/or rheumatoid arthritis, subsets of T-bet expressing B cells, known as age-associated B cells (CD19+CD11c+CD21-T-bet+) and/or double-negative B cells (CD19+IgD-CD27-T-bet+), display an expansion and seem to drive disease pathogenesis...
April 22, 2024: Clinical and Experimental Immunology
https://read.qxmd.com/read/38646719/efficacy-and-safety-of-bimekizumab-in-the-treatment-of-psoriatic-arthritis-a-systematic-review-and-meta-analysis
#7
REVIEW
Qin-Yi Su, Liu Yang, Ting-Yu Cao, Hai-Ying Dang, Zhuo-Chen Han, Jia-Jing Cao, He-Yi Zhang, Ting Cheng, Sheng-Xiao Zhang, Yue-Hong Huo
BACKGROUND: Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA. RESEARCH DESIGN AND METHODS: A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA...
April 22, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38646520/utilizing-noncatalytic-ace2-protein-mutant-as-a-competitive-inhibitor-to-treat-sars-cov-2-infection
#8
JOURNAL ARTICLE
Shengjiang Liu, Haifeng Chen, Xiangqun Chen, Ningguang Luo, Sameera Peraramelli, Xiaoming Gong, Mingwei John Zhang, Li Ou
INTRODUCTION: Angiotensin converting-enzyme 2 (ACE2) is an enzyme catalyzing the conversion of angiotensin 2 into angiotensin 1-7. ACE2 also serves as the receptor of several coronaviruses, including SARS-CoV-1 and SARS-CoV-2. Therefore, ACE2 could be utilized as a therapeutic target for treating these coronaviruses, ideally lacking enzymatic function. METHODS: Based on structural analysis, specific mutations were introduced to generate mutants of ACE2 and ACE2-Fc (fusion protein of ACE2 and Fc region of IgG1)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38631949/safe-plant-hsp90-adjuvants-elicit-an-effective-immune-response-against-sars-cov2-derived-rbd-antigen
#9
JOURNAL ARTICLE
Victor A Ramos-Duarte, Alejandro Orlowski, Carolina Jaquenod de Giusti, Mariana G Corigliano, Ariel Legarralde, Luisa F Mendoza-Morales, Agustín Atela, Manuel A Sánchez, Valeria A Sander, Sergio O Angel, Marina Clemente
To better understand the role of pHsp90 adjuvant in immune response modulation, we proposed the use of the Receptor Binding Domain (RBD) of the Spike protein of SARS-CoV2, the principal candidate in the design of subunit vaccines. We evaluated the humoral and cellular immune responses against RBD through the strategy "protein mixture" (Adjuvant + Antigen). The rRBD adjuvanted with rAtHsp81.2 group showed a higher increase of the anti-rRBD IgG1, while the rRBD adjuvanted with rNbHsp90.3 group showed a significant increase in anti-rRBD IgG2b/2a...
April 17, 2024: Vaccine
https://read.qxmd.com/read/38631146/hydrangea-serrata-extract-attenuates-pm-exacerbated-airway-inflammation-in-the-caras-model-by-modulating-the-il-33-st2-nf-%C3%AE%C2%BAb-signaling-pathway
#10
JOURNAL ARTICLE
Juan Jin, Thi Van Nguyen, Yuna Jiang, Zhen Nan Yu, Chang Ho Song, So-Young Lee, Hee Soon Shin, Ok Hee Chai
Particulate matter (PM) significantly contributes to the global health crisis of respiratory diseases. It is known to induce and exacerbate conditions such as asthma and respiratory infections. Long exposure to PM can increase the risk of combined allergic rhinitis and asthma syndrome (CARAS). Although therapeutic drugs can be used to improve symptoms of respiratory diseases caused by PM, their usage is often accompanied by side effects. Therefore, many studies are being conducted to discover functional food materials that can more effectively treat respiratory diseases while minimizing the side effects of these therapeutic drugs...
April 16, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38621620/differential-protective-impact-of-peptide-vaccine-formulae-targeting-the-lung-and-liver-stage-of-challenge-schistosoma-mansoni-infection-in-mice
#11
JOURNAL ARTICLE
Hatem Tallima, Menerva M Tadros, Rashika El Ridi
The study aimed to elicit protective immune responses against murine schistosomiasis mansoni at the parasite lung- and liver stage. Two peptides showing amino acid sequence similarity to gut cysteine peptidases, which induce strong memory immune effectors in the liver, were combined with a peptide based on S. mansoni thioredoxin peroxidase (TPX), a prominent lung-stage schistosomula excretory-secretory product, and alum as adjuvant. Only one of the 2 cysteine peptidases-based peptides in a multiple antigenic peptide construct (MAP-3 and MAP-4) appeared to adjuvant protective immune responses induced by the TPX peptide in a MAP form...
April 13, 2024: Acta Tropica
https://read.qxmd.com/read/38621471/icos-agonist-vopratelimab-modulates-follicular-helper-t-cells-and-improves-b-cell-function-in-common-variable-immunodeficiency
#12
JOURNAL ARTICLE
Ali Sepahi, Hsi-En Ho, Prapti Vyas, Benjamin Umiker, Katalin Kis-Toth, Dmitri Wiederschain, Lin Radigan, Charlotte Cunningham-Rundles
Common variable immunodeficiency (CVID) is an immune defect characterized by hypogammaglobulinemia and impaired development of B cells into plasma cells. As follicular helper T cells (TFH ) play a central role in humoral immunity, we examined TFH cells in CVID, and investigated whether an inducible T cell co-stimulator (ICOS) agonist, vopratelimab, could modulate TFH , B cell interactions and enhance immunoglobulin production. CVID subjects had decreased TFH17 and increased TFH1 subsets; this was associated with increased transitional B cells and decreased IgG+ B and IgD- IgM- CD27+ memory B cells...
April 13, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://read.qxmd.com/read/38616780/igg1-glycosylation-highlights-premature-aging-in-down-syndrome
#13
JOURNAL ARTICLE
Bianca M M Streng, Julie Van Coillie, Joanne G Wildenbeest, Rob S Binnendijk, Gaby Smits, Gerco den Hartog, Wenjun Wang, Jan Nouta, Federica Linty, Remco Visser, Manfred Wuhrer, Gestur Vidarsson, Louis J Bont
Down syndrome (DS) is characterized by lowered immune competence and premature aging. We previously showed decreased antibody response following SARS-CoV-2 vaccination in adults with DS. IgG1 Fc glycosylation patterns are known to affect the effector function of IgG and are associated with aging. Here, we compare total and anti-spike (S) IgG1 glycosylation patterns following SARS-CoV-2 vaccination in DS and healthy controls (HC). Total and anti-Spike IgG1 Fc N-glycan glycoprofiles were measured in non-exposed adults with DS and controls before and after SARS-CoV-2 vaccination by liquid chromatography-mass spectrometry (LC-MS) of Fc glycopeptides...
April 15, 2024: Aging Cell
https://read.qxmd.com/read/38615070/influenza-antibody-breadth-and-effector-functions-are-immune-correlates-from-acquisition-of-pandemic-infection-of-children
#14
JOURNAL ARTICLE
Janice Z Jia, Carolyn A Cohen, Haogao Gu, Milla R McLean, Raghavan Varadarajan, Nisha Bhandari, Malik Peiris, Gabriel M Leung, Leo L M Poon, Tim Tsang, Amy W Chung, Benjamin J Cowling, Nancy H L Leung, Sophie A Valkenburg
Cross-reactive antibodies with Fc receptor (FcR) effector functions may mitigate pandemic virus impact in the absence of neutralizing antibodies. In this exploratory study, we use serum from a randomized placebo-controlled trial of seasonal trivalent influenza vaccination in children (NCT00792051) conducted at the onset of the 2009 H1N1 pandemic (pH1N1) and monitored for infection. We found that seasonal vaccination increases pH1N1 specific antibodies and FcR effector functions. Furthermore, prospective baseline antibody profiles after seasonal vaccination, prior to pH1N1 infection, show that unvaccinated uninfected children have elevated ADCC effector function, FcγR3a and FcγR2a binding antibodies to multiple pH1N1 proteins, past seasonal and avian (H5, H7 and H9) strains...
April 13, 2024: Nature Communications
https://read.qxmd.com/read/38607319/structural-characterization-of-a-pathogenic-antibody-underlying-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt
#15
JOURNAL ARTICLE
Son N Nguyen, Si-Hung Le, Daniil G Ivanov, Nikola Ivetic, Ishac Nazy, Igor A Kaltashov
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but dangerous side effect of adenoviral-vectored COVID-19 vaccines. VITT had been linked to production of autoantibodies recognizing platelet factor 4 (PF4). Here, we characterize anti-PF4 antibodies obtained from a VITT patient's blood. Intact mass measurements indicate that a significant fraction of these antibodies represent a limited number of clones. MS analysis of large antibody fragments (the light chain and the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire and reveals the presence of a mature complex biantennary N -glycan within the Fd segment...
April 12, 2024: Analytical Chemistry
https://read.qxmd.com/read/38607316/a-systemic-approach-to-identifying-sequence-frameworks-that-decrease-mab-production-in-a-transient-chinese-hamster-ovary-cell-expression-system
#16
JOURNAL ARTICLE
Alana C Szkodny, Kelvin H Lee
Monoclonal antibodies (mAbs) are often engineered at the sequence level for improved clinical performance yet are rarely evaluated prior to candidate selection for their "developability" characteristics, namely expression, which can necessitate additional resource investments to improve the manufacturing processes for problematic mAbs. A strong relationship between primary sequence and expression has emerged, with slight differences in amino acid sequence resulting in titers differing by up to an order of magnitude...
April 12, 2024: Biotechnology Progress
https://read.qxmd.com/read/38602517/immunoglobulin-genes-and-severity-of-covid-19
#17
JOURNAL ARTICLE
Daniel Vázquez-Coto, Christine Kimball, Guillermo M Albaiceta, Laura Amado-Rodríguez, Marta García-Clemente, Juan Gómez, Eliecer Coto, Janardan P Pandey
There is tremendous interindividual and interracial variability in the outcome of SARS-CoV-2 infection, suggesting the involvement of host genetic factors. Here, we investigated whether IgG allotypes GM (γ marker) 3 and GM 17, genetic markers of IgG1, contributed to the severity of COVID-19. IgG1 plays a pivotal role in response against SARS-CoV-2 infection. We also investigated whether these GM alleles synergistically/epistatically with IGHG3 and FCGR2A alleles-which have been previously implicated in COVID-19-modulated the extent of COVID-19 severity...
April 11, 2024: Immunogenetics
https://read.qxmd.com/read/38601919/-in-vitro-evaluation-of-the-binding-activity-of-novel-mouse-igg1-opsonic-monoclonal-antibodies-to-mycobacterium-tuberculosis-and-other-selected-mycobacterial-species
#18
JOURNAL ARTICLE
Kudzai B Nyazema, Bong-Akee Shey, Clara J Sei, Remco P H Peters, Nontuthuko E Maningi, Gerald W Fischer, P Bernard Fourie
Antimicrobial resistance alongside other challenges in tuberculosis (TB) therapeutics have stirred renewed interest in host-directed interventions, including the role of antibodies as adjunct therapeutic agents. This study assessed the binding efficacy of two novel IgG1 opsonic monoclonal antibodies (MABs; GG9 & JG7) at 5, 10, and 25 µg/mL to live cultures of Mycobacterium tuberculosis, M. avium , M. bovis , M. fortuitum , M. intracellulare , and M. smegmatis American Type Culture Collection laboratory reference strains, as well as clinical susceptible, multi-drug resistant, and extensively drug resistant M...
May 2024: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
https://read.qxmd.com/read/38600747/a-real%C3%A2-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for-daratumumab
#19
JOURNAL ARTICLE
Xiaolin Yun, Yingying Zhou, Danna Wu, Yuanbo Liu, Qiongshi Wu
BACKGROUND: Daratumumab, a first-in-class humanized IgG1κ monoclonal antibody that targets the CD38 epitope, has been approved for treatment of multiple myeloma by FDA. The current study was to evaluate daratumumab-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of daratumumab-associated AEs...
April 10, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38600082/antigen-specific-fab-profiling-achieves-molecular-resolution-analysis-of-human-autoantibody-repertoires-in-rheumatoid-arthritis
#20
JOURNAL ARTICLE
Eva Maria Stork, Danique M H van Rijswijck, Karin A van Schie, Max Hoek, Theresa Kissel, Hans Ulrich Scherer, Tom W J Huizinga, Albert J R Heck, Rene E M Toes, Albert Bondt
The presence of autoantibodies is a defining feature of many autoimmune diseases. The number of unique autoantibody clones is conceivably limited by immune tolerance mechanisms, but unknown due to limitations of the currently applied technologies. Here, we introduce an autoantigen-specific liquid chromatography-mass spectrometry-based IgG1 Fab profiling approach using the anti-citrullinated protein antibody (ACPA) repertoire in rheumatoid arthritis (RA) as an example. We show that each patient harbors a unique and diverse ACPA IgG1 repertoire dominated by only a few antibody clones...
April 10, 2024: Nature Communications
keyword
keyword
111034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.